Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 40.00
Ask: 40.90
Change: 0.00 (0.00%)
Spread: 0.90 (2.25%)
Open: 40.00
High: 40.00
Low: 40.00
Prev. Close: 40.00
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Market Authorisation Update

3 May 2022 07:00

RNS Number : 9826J
Benchmark Holdings PLC
03 May 2022
 

3 May 2022

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Ectosan® Vet

Variation to Marketing Authorisation enabling a second use of treatment water

An important milestone towards optimal efficiency of Benchmark's transformational sea lice solution

 

Benchmark (LSE: BMK), the aquaculture biotechnology company, is pleased to announce that it has been granted a variation to its Marketing Authorisation ("MA") for Ectosan® Vet from the Norwegian Medicines Agency ("NoMA").

 

This variation to the MA enables the re-use of the treatment water for a second batch of fish, subject to water quality being maintained to the satisfaction of the prescribing veterinarian, therefore increasing the efficiency of treatments. This means a producer will be able to treat a salmon farm more efficiently with a solution that delivers more than 99% efficacy, promotes animal welfare, reduces mortality and protects the environment - driving sustainability in the industry.

 

This MA variation represents a further important step towards our goal of optimising the efficiency of our sea lice solution, and further trials are ongoing to support multiple re-use of treatment water.

 

 Trond Williksen, CEO, commented:

 

"We are very pleased to have been granted a variation to the Marketing Authorisation from the Norwegian Medicines Agency. This represents an important milestone for the Company and for the industry. Ectosan® Vet and CleanTreat® is a much needed solution for the industry which continues to show excellent results with efficacy above 99% as well as good operational efficiency. It is the first medicinal solution brought to the Norwegian market in over ten years which addresses one of the biggest challenges in salmon production, while improving animal welfare, reducing mortality and protecting the environment."

 

Enquiries:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

 

 

 

MHP

 

Katie Hunt/Charlie Protheroe/Fergal Bettridge-Boyd

Tel: 020 3128 8990

benchmark@mhpc.com

 

 

 

 

 

About Benchmark 

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBLLLBLELZBBL
Date   Source Headline
22nd Jan 20244:27 pmRNSForm 8.3 - Benchmark Holdings Plc
22nd Jan 20241:48 pmRNSForm 8.3 -Benchmark Holdings Plc
22nd Jan 20247:00 amRNSStrategic Review and Formal Sale Process
16th Jan 20245:30 pmRNSNotice of AGM - correction
9th Jan 20245:15 pmRNSPosting of Notice of AGM
12th Dec 20235:50 pmRNSNew Long Term Incentive Plan and PDMR Dealing
12th Dec 20231:54 pmRNSDirectorate Change
7th Dec 202312:00 pmRNSPublication of Annual Report and Notice of AGM
29th Nov 20237:01 amRNSDirectorate Change
29th Nov 20237:01 amRNSQ4 Results
29th Nov 20237:00 amRNSFull Year Results
6th Nov 202310:24 amRNSNotice of Q4 and Full Year Results
31st Oct 20237:00 amRNSTotal Voting Rights
10th Oct 202311:26 amRNSNew salmon broodstock licenses - correction
10th Oct 202310:06 amRNSGrant of two new salmon broodstock licenses
29th Sep 20237:00 amRNSTotal Voting Rights
21st Sep 20237:00 amRNSBlock Listing Six Monthly Return
31st Aug 20237:00 amRNSTotal Voting Rights
24th Aug 20237:00 amRNSQ3 Results
11th Aug 20237:00 amRNSNotice of Q3 Results
31st Jul 20237:00 amRNSTotal Voting Rights
30th Jun 20237:00 amRNSAppointment of Non-Executive Director
30th Jun 20237:00 amRNSTotal Voting Rights
31st May 20237:00 amRNSTotal Voting Rights
30th May 20233:30 pmRNSPCA Shareholding
30th May 202311:55 amRNSHolding(s) in Company
23rd May 20237:00 amRNSSecond Quarter and Interim results
5th May 20237:00 amRNSNotice of Q2 and Interim Results
28th Apr 20237:00 amRNSTotal Voting Rights
21st Apr 20231:00 pmRNSDirector Share Options
17th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSListing of Green NOK Bond
31st Mar 20237:00 amRNSTotal Voting Rights
21st Mar 20235:33 pmRNSShare Premium Reduction
21st Mar 20237:00 amRNSBlock Listing Six Monthly Return
17th Mar 20236:09 pmRNSHolding(s) in Company
2nd Mar 202311:12 amRNSDirector Dealings
28th Feb 20239:00 amRNSTotal Voting Rights
28th Feb 20237:00 amRNSQ1 Results
17th Feb 20237:00 amRNSAcquisition of remaining minority interest
16th Feb 20236:03 pmRNSResult of AGM
14th Feb 202311:45 amRNSNotice of Q1 Results
31st Jan 20237:00 amRNSTotal Voting Rights
27th Jan 20234:40 pmRNSSecond Price Monitoring Extn
27th Jan 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn
17th Jan 20234:35 pmRNSPrice Monitoring Extension
11th Jan 20238:00 amRNSPosting of Notice of AGM
30th Dec 20227:00 amRNSTotal Voting Rights
16th Dec 20229:58 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.